Co-Authors
This is a "connection" page, showing publications co-authored by RENATA FERRAROTTO and ERICH M STURGIS.
Connection Strength
0.804
-
Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther. 2021; 8(1):213-222.
Score: 0.050
-
Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther. 2021; 8(1):234-247.
Score: 0.050
-
Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngol Head Neck Surg. 2021 05 01; 147(5):469-478.
Score: 0.049
-
Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
Score: 0.048
-
Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer. 2021 02; 124(3):628-633.
Score: 0.047
-
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.
Score: 0.047
-
Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
Score: 0.047
-
Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
Score: 0.046
-
Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):929-935.
Score: 0.046
-
Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139.
Score: 0.046
-
Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22.
Score: 0.044
-
Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
Score: 0.044
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.043
-
Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
Score: 0.042
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.
Score: 0.040
-
Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
Score: 0.039
-
Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
Score: 0.039
-
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
Score: 0.038